Patent application number | Description | Published |
20080207552 | Decoy compositions for treating and preventing brain diseases and disorders - The present invention provides introduction of NF-κB decoy oligodeoxynucleotide into rat cranial nerve through a carotid artery during global brain ischemia. Polymerase chain reaction demonstrated that one hour after global brain ischemia, transfected NF-κB decoy oligodeoxynucleotide effectively suppressed expression of tumor necrosis factor α, interleukin 1β and intracellular adhesion molecule 1 messenger RNAs. Terminal deoxynucleotidyl transferase-mediated deoxyuridine nick-end labeling staining and immunohistochemistry using microtubule-associated protein 2 demonstrated that transfected NF-κB decoy oligodeoxynucleotide significantly attenuated neuronal damage seven days after global brain ischemia. Therapeutic transfection of NF-κB decoy oligodeoxynucleotide during brain ischemia may be effective for attenuation of neuronal damage, suggesting a strategy for protecting the cerebrum from global ischemia. | 08-28-2008 |
20080213348 | Agents for gene therapy of cerebrovascular disorders - The present invention provides novel methods for treating cerebrovascular disorders, in which HGF is overexpressed by introducing an HGF gene. The methods of this invention using an HGF gene enable active treatment of cerebrovascular disorders, such as cerebral infarction, by gene transfer, and enable the maintenance of neuronal function and the suppression of infarcted areas in patients for whom appropriate treatment methods were unavailable until now. | 09-04-2008 |
20080268030 | Gene therapy for diabetic ischemic disease - It is possible to stimulate the angiogenesis of an ischemic site declined by diabetes and to recuperate ischemic disease by administering HGF (hepatocyte growth factor) gene to the diabetic ischemic. | 10-30-2008 |
20080312145 | Agent for Regulating Bone Formation - The present invention provides preventive, ameliorating, and/or therapeutic agents for diseases caused by a disturbed balance between bone formation and bone resorption. The decoys of the present invention induce normal bone metabolism by inhibiting the differentiation-inducing factors of cells involved in bone metabolism. For example, bone resorption can be controlled by using a decoy of the present invention to inhibit NF-κB, a transcriptional regulatory factor that regulates osteoclast differentiation. This method uses a mechanism different from those of previous pharmaceutical agents; therefore, one can expect it to be effective for cases in which existing pharmaceutical agents were not effective. | 12-18-2008 |
20090074788 | Antibody Against Periostin, and a Pharmaceutical Composition comprising it for Preventing or Treating a Disease in which Periostin is Involved - The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method. | 03-19-2009 |
20090082263 | DRUG AND METHOD FOR IMPROVING BRAIN FUNCTION - It is intended to provide a novel remedy for improving the brain function or preventing the same from worsening and a novel administration method for the remedy. Namely, a composition for preventing the brain function from worsening or improving the brain function which contains a cell growth factor. It is preferred that this cell growth factor is one selected from the group consisting of vascular endothelial growth factors (VEGFs), fibroblast growth factors (FGFs) and hepatocyte growth factors (HGFs). A method for preventing the brain function from worsening or improving the brain function which comprises the step of administering a cell growth factor to a patient. | 03-26-2009 |
20090087916 | Assay method for identifying drug candidate - The present invention provides a method of identifying a drug candidate capable of removing peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which includes measuring, in the presence of a test compound, the concentration of a soluble peptide, a soluble oligopeptide, a soluble polypeptide or a soluble protein in an equilibrium state in a solvent. Moreover, the present invention provides a dissolution promoter to remove peptide, oligopeptide, polypeptide or protein from fibril or aggregate, which contains the compound obtained by the identification method as an active ingredient. | 04-02-2009 |
20090105183 | Pharmaceutical composition containing decoy and method of using the same - A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease. | 04-23-2009 |
20100040686 | BIOMATERIAL - The present invention provides a biomaterial which releases slowly a biologically active substance acting only on bone cell regeneration, in order to compensate for bone or alveolar bone lost due to surgery, accident or the like. Specifically, the invention relates to a biomaterial containing an osteogenic factor adsorbed on a porous material selected from hydroxyapatite, calcium phosphate, β-TCP (tricalcium phosphate [β-Ca | 02-18-2010 |
20100105762 | THERAPEUTIC AGENT FOR PERIODONTAL DISEASE AND ALVEOLAR BONE LOSS DUE TO SURGERY - By suppressing transcription activation by NFκB, the present invention was demonstrated to suppress alveolar bone resorption in periodontal disease models, and promote restoration of alveolar bone in periodontal disease-caused bone defect models. Therefore, the present invention provides agents for treating, preventing, and improving periodontal diseases and alveolar bone defects caused by surgical operations, said agents comprising as an active ingredient, a NFκB decoy or such that suppresses the transcription activity of NFκB. | 04-29-2010 |
20100130567 | MEDICAL AGENT FOR PREVENTION OR TREATMENT OF ALZHEIMER 'S DISEASE - A method of treating or preventing Alzheimer's disease or mild cognitive impairment which is an early state of cognitive impairment including Alzheimers' disease by administering a pharmacologically effective amount of an angiotensin II receptor blocker. A method of improving cerebral circulation or cerebral blood flow disorder by administering a pharmacologically effective amount of an angiotensin II receptor blocker. A method of treating or preventing amyloid β-induced brain disfunction by administering a pharmacologically effective amount of an angiotensin II receptor blocker. | 05-27-2010 |
20100240735 | Pharmaceutical Compositions for Angiogenic Therapy - The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient. | 09-23-2010 |
20100311823 | AGENT FOR REGULATING BONE FORMATION - The present invention provides preventive, ameliorating, and/or therapeutic agents for diseases caused by a disturbed balance between bone formation and bone resorption. The decoys of the present invention induce normal bone metabolism by inhibiting the differentiation-inducing factors of cells involved in bone metabolism. For example, bone resorption can be controlled by using a decoy of the present invention to inhibit NF-κB, a transcriptional regulatory factor that regulates osteoclast differentiation. This method uses a mechanism different from those of previous pharmaceutical agents; therefore, one can expect it to be effective for cases in which existing pharmaceutical agents were not effective. | 12-09-2010 |
20100331395 | DECOY-CONTAINING PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING THE SAME - A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. The pharmaceutically acceptable carrier may be a hydrophilic polymer. | 12-30-2010 |
20110022027 | DRUG-ELUTING CATHETER AND METHOD OF MANUFACTURING THE SAME - Biocompatible nanoparticles | 01-27-2011 |
20110045061 | GENE THERAPY FOR DIABETIC ISCHEMIC DISEASE - It is possible to stimulate the angiogenesis of an ischemic site declined by diabetes and to recuperate ischemic disease by administering HGF (hepatocyte growth factor) gene to the diabetic ischemic. | 02-24-2011 |
20110160132 | LYMPHANGIOGENESIS-PROMOTING AGENTS - Described herein is the discovery that HGFs activate the growth and migration of lymphatic endothelial cells and thereby promote lymphangiogenesis. The present invention is based on this finding, and provides lymphangiogenesis-promoting agents comprising as active ingredients HGFs, or proteins or compounds functionally equivalent thereto. Based on the finding described above, the present invention also provides methods for promoting lymphangiogenesis which comprise the step of locally administering HGFs or proteins functionally equivalent thereto to affected areas in patients with lymphedema. | 06-30-2011 |
20110250261 | CIRCULAR DUMBBELL DECOY OLIGODEOXYNUCLEOTIDES (CDODN) CONTAINING DNA BINDINGS SITES OF TRANSCRIPTION - The present invention provides a circular dumbbell oligodeoxynucleotide (CDODN) comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of a transcriptional factor. The present invention further provides a pharmaceutical composition comprising said CDODN. The pharmaceutical composition can be used for treating and/or preventing a disease or disorder related to such a transcriptional factor. The present invention also provides a method for treating and/or preventing a disease or disorder related to such a transcriptional factor, comprising administering to the subject a therapeutically effective amount of a CDODN comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of the transcriptional factor. | 10-13-2011 |
20110259811 | DIALYSIS PROBE - Provided is a dialysis probe capable of stably performing an analysis with high accuracy for a long period of time even if the inflow and outflow rates of a perfusate are not completely equalized. | 10-27-2011 |
20120058572 | ANTIBODY AGAINST PERIOSTIN, AND A PHARMACEUTICAL COMPOSITION COMPRISING IT FOR PREVENTING OR TREATING A DISEASE IN WHICH PERIOSTIN IS INVOLVED - The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method. | 03-08-2012 |
20120122766 | Novel Polypeptide Having Angiogenesis-Inducing Activity And Antibacterial Activity, And Use Thereof For Medical Purposes - Novel polypeptides which have an excellent angiogenesis-inducing activity and an excellent antibacterial activity and medical uses thereof are disclosed. The amino acid sequences of the novel polypeptides are shown in any one of SEQ ID NOs:1 to 6. These polypeptides have angiogenesis-inducing and antibacterial activities. Such polypeptides are useful for the prevention, amelioration or treatment of skin wounds caused by a cut wound, surgical wound, erosion, burn, decubitus, intractable wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease or arteriosclerosis obliteran, and for the prevention, amelioration or treatment of bacterial infection in such skin wounds, and the like. | 05-17-2012 |
20120302614 | METHOD FOR IMPROVING CEREBRAL CIRCULATION OR TREATING A CEREBRAL BLOOD FLOW DISORDER - A method for improving cerebral circulation or treating a cerebral blood flow disorder, comprising administering a pharmacologically effective amount of an angiotensin II receptor blocker to a human. | 11-29-2012 |
20130225961 | DIALYSIS PROBE - A dialysis probe includes a tubular dialysis membrane sealed at its tip, a support tube coupled at a tip to a rear end of the dialysis membrane, a cap portion for securing a rear end of the support tube, an inlet conduit extending through the cap portion toward the tip of the dialysis membrane within a space to guide a perfusate into the space, an outlet conduit extending through the cap portion toward the tip of the dialysis membrane within the space to guide the perfusate in the space outside the space, and at least one air-exposure through-hole provided in the cap portion for maintaining the space at atmospheric pressure. The inlet conduit has a longer protruding length from the rear end of the support tube when compared to the outlet conduit. | 08-29-2013 |
20140086944 | DNA VACCINE CONTAINING SPECIFIC EPITOPE OF APOLIPOPROTEIN (a) - The present invention provides an agent for the treatment or prophylaxis of arteriosclerosis comprising an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of apolipoprotein (a), wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide. | 03-27-2014 |
20140099335 | DNA VACCINE - The present invention provides a therapeutic or improving agent for a lifestyle-related disease, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of the lifestyle-related disease-related factor, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide. | 04-10-2014 |